You’re reading the web version of STAT’s popup newsletter, AACR in 30 seconds, your guide to what’s happening at the American Association of Cancer Researchers’ annual meeting. This is the last edition of our pop-up newsletter.
We hope you’ve learned as much as we have. If you’re not already a STAT+ subscriber, consider it!
There’s currently a  60% off promotion  on annual subscriptions. In the meantime, thanks for joining us.
Overcoming resistance and RevMed’s next drug? In case you missed it, Revolution Medicines’ sessions yesterday were jam-packed with conference attendees.
While most of the media coverage focused on the daraxonrasib in frontline pancreatic cancer data, the company also revealed some activity in a new compound, RM-055. CEO Mark Goldsmith described it as being part of a new class of “catalytic inhibitors,” since it can slice off a phosphate from GTP-RAS, or the “on” form of RAS, and turn the protein off.
This brief originated as the final issue of STAT’s pop-up AACR newsletter, summarizing notable developments presented at the American Association for Cancer Research annual meeting.
It is framed as a short conference briefing and directs readers to STAT+ for expanded coverage.
No formal study report or trial protocol is provided in the source.
Revolution Medicines drew substantial attendance at its sessions.
Public attention centered on daraxonrasib data in first-line pancreatic cancer, but the company also disclosed preclinical or early-stage activity for a different molecule, RM-055.
The source does not provide detailed trial design, patient numbers, or outcome metrics for either agent.
RM-055 was described by the company’s CEO as representing a novel class of “catalytic inhibitors.” The proposed mechanism is removal of a phosphate from GTP-bound RAS, thereby converting the active RAS protein to its inactive form.
This catalytic activity is suggested to enable inactivation of multiple mutant RAS molecules per drug molecule.
The newsletter cites the mechanistic rationale that tumors can resist conventional RAS inhibitors by amplifying mutant RAS expression, increasing the pool of active oncoprotein and overwhelming inhibitors.
A catalytic mechanism that inactivates many RAS proteins could, in principle, address that specific resistance pathway.
The source does not report experimental validation, comparative data, or clinical efficacy.
The piece lacks detailed methods, preclinical or clinical data, safety information, and independent corroboration.
Efficacy, dosing, study endpoints, and adverse-event profiles were not reported in the source.